Kythera Biopharmaceuticals Stock Price, News & Analysis (NASDAQ:KYTH)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Kythera Biopharmaceuticals (NASDAQ:KYTH)

Kythera Biopharmaceuticals logoKYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Receive KYTH News and Ratings via Email

Sign-up to receive the latest news and ratings for KYTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorBio Therapeutic Drugs
SymbolNASDAQ:KYTH
CUSIP50157010
WebN/A
Phone+1-818-5874500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($4.64)
Net IncomeN/A
Net Margins-12,900.69%
Return on Equity-93.97%
Return on Assets-72.56%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Kythera Biopharmaceuticals (NASDAQ:KYTH) Frequently Asked Questions

What is Kythera Biopharmaceuticals' stock symbol?

Kythera Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KYTH."

How were Kythera Biopharmaceuticals' earnings last quarter?

Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) released its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.10) by $0.34. The biopharmaceutical company had revenue of $288 million for the quarter. Kythera Biopharmaceuticals had a negative net margin of 12,900.69% and a negative return on equity of 93.97%. View Kythera Biopharmaceuticals' Earnings History.

Who are some of Kythera Biopharmaceuticals' key competitors?

How do I buy Kythera Biopharmaceuticals stock?

Shares of Kythera Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Kythera Biopharmaceuticals?

Kythera Biopharmaceuticals' mailing address is 27200 Agoura Rd Ste 200, AGOURA HILLS, CA 91301-5127, United States. The biopharmaceutical company can be reached via phone at +1-818-5874500.


MarketBeat Community Rating for Kythera Biopharmaceuticals (KYTH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  109
MarketBeat's community ratings are surveys of what our community members think about Kythera Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kythera Biopharmaceuticals (NASDAQ:KYTH) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Kythera Biopharmaceuticals (NASDAQ:KYTH) Earnings History and Estimates Chart

Earnings by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)

Kythera Biopharmaceuticals (NASDAQ KYTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2015Q2($1.10)($1.44)$288.00 millionViewN/AView Earnings Details
3/2/2015Q414($1.07)($1.07)ViewN/AView Earnings Details
8/7/2014Q2($0.83)($0.86)ViewListenView Earnings Details
5/8/2014Q1($0.67)($0.76)ViewListenView Earnings Details
3/17/2014Q413($0.69)($0.66)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.70)($0.67)ViewN/AView Earnings Details
5/13/2013Q1 2013($0.97)($0.77)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.76)($1.04)ViewN/AView Earnings Details
11/13/2012Q312($11.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Kythera Biopharmaceuticals (NASDAQ:KYTH) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Kythera Biopharmaceuticals (NASDAQ:KYTH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Kythera Biopharmaceuticals (NASDAQ KYTH) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Insider Trades by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)

Kythera Biopharmaceuticals (NASDAQ KYTH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/24/2015Frederick Beddingfield IIIinsiderSell110,638$74.91$8,287,892.58View SEC Filing  
9/24/2015John W. SmitherCFOSell53,835$74.90$4,032,241.50View SEC Filing  
9/23/2015Elisabeth SandovalinsiderSell83,122$74.90$6,225,837.80View SEC Filing  
9/23/2015Keith KleinGeneral CounselSell52,153$74.90$3,906,259.70View SEC Filing  
9/22/2015John W. SmitherCFOSell6,645$74.91$497,776.95View SEC Filing  
9/22/2015Keith KleinGeneral CounselSell10,589$74.90$793,116.10View SEC Filing  
9/18/2015John W. SmitherCFOSell1,054$74.95$78,997.30View SEC Filing  
9/1/2015Camille D SamuelsDirectorSell250$74.72$18,680.00View SEC Filing  
6/25/2015Frederick Beddingfield IIIInsiderSell30,583$75.66$2,313,909.78View SEC Filing  
6/25/2015John W SmitherCFOSell4,600$75.50$347,300.00View SEC Filing  
5/1/2015Keith R LeonardCEOSell13,000$44.93$584,090.00View SEC Filing  
4/30/2015Elisabeth SandovalInsiderSell1,654$45.55$75,339.70View SEC Filing  
4/30/2015John W SmitherCFOSell2,041$45.49$92,845.09View SEC Filing  
4/30/2015Keith R LeonardCEOSell5,557$45.29$251,676.53View SEC Filing  
4/15/2015Keith R LeonardCEOSell2,709$50.52$136,858.68View SEC Filing  
4/1/2015Keith R LeonardCEOSell13,548$48.14$652,200.72View SEC Filing  
3/16/2015Keith R LeonardCEOSell5,312$50.16$266,449.92View SEC Filing  
3/9/2015Nathaniel E DavidDirectorSell6,185$55.00$340,175.00View SEC Filing  
3/5/2015John W SmitherCFOSell4,200$48.09$201,978.00View SEC Filing  
3/5/2015Nathaniel E DavidDirectorSell12,375$48.49$600,063.75View SEC Filing  
3/2/2015Keith R LeonardCEOSell10,625$40.94$434,987.50View SEC Filing  
3/2/2015Nathaniel E DavidDirectorSell1,875$40.78$76,462.50View SEC Filing  
2/18/2015John W SmitherCFOSell2,000$41.00$82,000.00View SEC Filing  
2/17/2015Keith R LeonardCEOSell4,165$40.46$168,515.90View SEC Filing  
2/2/2015Keith R LeonardCEOSell6,249$36.70$229,338.30View SEC Filing  
2/2/2015Nathaniel E DavidDirectorSell1,715$36.76$63,043.40View SEC Filing  
1/29/2015John W SmitherCFOSell1,000$38.00$38,000.00View SEC Filing  
1/23/2015John W SmitherCFOSell3,000$35.65$106,950.00View SEC Filing  
1/16/2015Camille D SamuelsDirectorSell250$36.70$9,175.00View SEC Filing  
1/2/2015Keith R LeonardCEOSell6,120$35.37$216,464.40View SEC Filing  
1/2/2015Nathaniel E DavidDirectorSell1,680$35.30$59,304.00View SEC Filing  
12/1/2014Keith R LeonardCEOSell5,994$37.60$225,374.40View SEC Filing  
12/1/2014Nathaniel E DavidDirectorSell1,645$37.67$61,967.15View SEC Filing  
11/3/2014Keith R LeonardCEOSell5,865$34.95$204,981.75View SEC Filing  
11/3/2014Nathaniel E DavidDirectorSell1,610$34.90$56,189.00View SEC Filing  
10/23/2014Keith R LeonardCEOSell1,913$35.13$67,203.69View SEC Filing  
10/1/2014Keith R LeonardCEOSell3,826$32.55$124,536.30View SEC Filing  
10/1/2014Nathaniel E DavidDirectorSell1,350$32.60$44,010.00View SEC Filing  
9/2/2014Nathaniel E DavidDirectorSell1,540$37.37$57,549.80View SEC Filing  
8/4/2014Keith R LeonardCEOSell1,828$35.10$64,162.80View SEC Filing  
8/4/2014Nathaniel E DavidDirectorSell1,505$33.08$49,785.40View SEC Filing  
8/1/2014Keith R LeonardCEOSell3,656$32.80$119,916.80View SEC Filing  
7/2/2014John W SmitherCFOSell2,250$40.00$90,000.00View SEC Filing  
7/2/2014Keith R LeonardCEOSell8,925$39.47$352,269.75View SEC Filing  
7/2/2014Nathaniel E DavidDirectorSell1,778$39.20$69,697.60View SEC Filing  
6/16/2014Keith R LeonardCEOSell1,743$36.58$63,758.94View SEC Filing  
6/2/2014Keith R LeonardCEOSell3,486$32.54$113,434.44View SEC Filing  
6/2/2014Nathaniel E DavidDirectorSell1,230$32.56$40,048.80View SEC Filing  
5/1/2014Keith LeonardCEOSell3,400$32.56$110,704.00View SEC Filing  
5/1/2014Nathaniel DavidDirectorSell1,200$32.60$39,120.00View SEC Filing  
4/1/2014Jeffrey WebsterVPSell4,000$39.36$157,440.00View SEC Filing  
4/1/2014Keith LeonardCEOSell13,260$39.08$518,200.80View SEC Filing  
3/20/2014John SmitherCFOSell1,125$43.78$49,252.50View SEC Filing  
3/3/2014Jeffrey WebsterVPSell4,000$49.55$198,200.00View SEC Filing  
3/3/2014Nathaniel DavidDirectorSell5,099$49.18$250,768.82View SEC Filing  
2/20/2014John SmitherCFOSell2,250$49.75$111,937.50View SEC Filing  
2/14/2014John SmitherCFOSell1,125$50.00$56,250.00View SEC Filing  
2/3/2014Jeffrey WebsterVPSell4,000$45.40$181,600.00View SEC Filing  
2/3/2014Keith LeonardCEOSell12,740$45.35$577,759.00View SEC Filing  
2/3/2014Nathaniel DavidDirectorSell5,000$45.31$226,550.00View SEC Filing  
1/21/2014John SmitherCFOSell1,125$42.54$47,857.50View SEC Filing  
1/2/2014Jeffrey WebsterVPSell4,000$37.38$149,520.00View SEC Filing  
1/2/2014Keith LeonardCEOSell12,480$37.38$466,502.40View SEC Filing  
12/2/2013Jeffrey WebsterVPSell4,000$38.69$154,760.00View SEC Filing  
12/2/2013Keith LeonardCEOSell12,220$38.95$475,969.00View SEC Filing  
12/2/2013Nathaniel DavidDirectorSell4,800$38.72$185,856.00View SEC Filing  
11/1/2013Jeffrey D WebsterVPSell4,000$44.90$179,600.00View SEC Filing  
11/1/2013Keith R LeonardCEOSell11,960$44.22$528,871.20View SEC Filing  
11/1/2013Nathaniel E DavidDirectorSell4,698$43.93$206,383.14View SEC Filing  
9/16/2013Keith LeonardCEOSell2,860$33.62$96,153.20View SEC Filing  
9/10/2013John W SmitherCFOSell40,000$30.02$1,200,800.00View SEC Filing  
9/10/2013Keith KleinGeneral CounselSell4,500$32.00$144,000.00View SEC Filing  
9/10/2013Nathaniel E DavidDirectorSell6,376$31.00$197,656.00View SEC Filing  
9/3/2013Jeffrey WebsterVPSell4,000$26.11$104,440.00View SEC Filing  
9/3/2013Keith LeonardCEOSell8,580$26.12$224,109.60View SEC Filing  
9/3/2013Nathaniel DavidDirectorSell3,375$26.12$88,155.00View SEC Filing  
8/1/2013Jeffrey D WebsterVPSell4,000$26.76$107,040.00View SEC Filing  
8/1/2013John W SmitherCFOSell10,000$26.80$268,000.00View SEC Filing  
8/1/2013Keith R LeonardCEOSell8,385$26.73$224,131.05View SEC Filing  
8/1/2013Nathaniel E DavidDirectorSell3,301$26.76$88,334.76View SEC Filing  
7/15/2013Keith R LeonardCEOSell1,365$28.90$39,448.50View SEC Filing  
7/1/2013Jeffrey D WebsterVPSell4,000$27.06$108,240.00View SEC Filing  
7/1/2013Keith R LeonardCEOSell8,190$27.10$221,949.00View SEC Filing  
7/1/2013Nathaniel E DavidDirectorSell3,225$27.07$87,300.75View SEC Filing  
6/28/2013Keith KleinGeneral CounselSell4,500$27.00$121,500.00View SEC Filing  
6/17/2013John W SmitherCFOSell6,000$26.00$156,000.00View SEC Filing  
6/17/2013Keith R LeonardCEOSell1,332$25.69$34,219.08View SEC Filing  
6/17/2013Nathaniel E DavidDirectorSell1,538$26.00$39,988.00View SEC Filing  
6/7/2013Jeffrey D WebsterVPSell4,000$25.00$100,000.00View SEC Filing  
6/3/2013Keith R LeonardCEOSell6,663$21.25$141,588.75View SEC Filing  
5/31/2013Jeffrey D WebsterVPSell4,000$22.26$89,040.00View SEC Filing  
5/1/2013Nathaniel E DavidDirectorSell2,625$21.42$56,227.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kythera Biopharmaceuticals (NASDAQ KYTH) News Headlines

Source:
DateHeadline
Pulmatrix (PULM) Appoints Amit Munshi to BoardPulmatrix (PULM) Appoints Amit Munshi to Board
www.streetinsider.com - June 16 at 7:14 AM
Pulmatrix (PULM) Appoints Amit Munshi to BoardPulmatrix (PULM) Appoints Amit Munshi to Board
www.streetinsider.com - June 16 at 7:14 AM
Amit D. Munshi Joins Pulmatrixs Board of DirectorsAmit D. Munshi Joins Pulmatrix's Board of Directors
www.prnewswire.com - June 16 at 7:14 AM
Amit D. Munshi Joins Pulmatrixs Board of DirectorsAmit D. Munshi Joins Pulmatrix's Board of Directors
www.prnewswire.com - June 16 at 7:14 AM
Neothetics: A Look Ahead - Seeking AlphaNeothetics: A Look Ahead - Seeking Alpha
seekingalpha.com - December 22 at 12:47 AM
Neothetics: A Look AheadNeothetics: A Look Ahead
seekingalpha.com - December 21 at 7:03 PM
Nohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with ... - GlobeNewswire (press release)Nohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 6:21 PM
6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE)6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE)
www.investopedia.com - November 19 at 8:28 AM
Alder BioPharmaceuticals (ALDR) CEO Randy Schatzman on Q3 ... - Seeking AlphaAlder BioPharmaceuticals' (ALDR) CEO Randy Schatzman on Q3 ... - Seeking Alpha
seekingalpha.com - October 28 at 9:25 AM
Anti-Aging Startup Raises $116 Million With Bezos Backing - BloombergAnti-Aging Startup Raises $116 Million With Bezos Backing - Bloomberg
www.bloomberg.com - October 28 at 9:25 AM
BlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders - Business Wire (press release)BlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders - Business Wire (press release)
www.businesswire.com - October 20 at 11:34 AM
Pfenex Inc. Announces Formation of Scientific Advisory Board - PR Newswire (press release)Pfenex Inc. Announces Formation of Scientific Advisory Board - PR Newswire (press release)
www.prnewswire.com - October 20 at 11:34 AM
Medical Aesthetics Market Worth $69,786 Million by 2021Medical Aesthetics Market Worth $69,786 Million by 2021
www.bizjournals.com - August 10 at 8:52 AM
MannKind (MNKD) Assumes Responsibility for Distribution of Afrezza; Launches Patient Reimbursement Programs - StreetInsider.comMannKind (MNKD) Assumes Responsibility for Distribution of Afrezza; Launches Patient Reimbursement Programs - StreetInsider.com
www.streetinsider.com - August 1 at 5:45 PM
Sienna Biopharmaceuticals Announces Second Closing of Series A Financing - Business Wire (press release)Sienna Biopharmaceuticals Announces Second Closing of Series A Financing - Business Wire (press release)
www.businesswire.com - July 13 at 6:17 PM

SEC Filings

Kythera Biopharmaceuticals (NASDAQ:KYTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kythera Biopharmaceuticals (NASDAQ:KYTH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kythera Biopharmaceuticals (NASDAQ KYTH) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.